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• p 1
Updat e of i nt roducti on
• p 8-9
Modif i cati on an d e xp ansion of G ui de l in e 6, an d i ts justi f icat i on an d ex p lanat ion The Guidelines aim to improve the quality of drug donations, not to hinder them. They are not an international regulation, but are intended to serve as a basis for national or institutional guidelines, to be reviewed, adapted and implemented by governments and organizations dealing with drug donations.
The original Guidelines were based on several rounds of consultation and comments by over 100 humanitarian organizations and individual experts. In 1996 WHO was requested by the World Health Assembly, in resolution WHA49.14, to review the experiences with the guidelines after one year. In autumn 1997 WHO's Action Programme on Essential Drugs therefore initiated a global review of first-year experiences. The results of the review are presented in the forthcoming document First-year experiences with the interagency guidelines for drug donations. The evaluation formed the basis for the changes in the text. In general, experiences with the Guidelines were very positive. But there were complaints that the authorities in some recipient countries strictly adhered to the Guidelines, without regard for the exceptions specifically included, and as a result useful donations were lost. For example, problems were reported with Guideline 6: "donated drugs should have a remaining shelf-life of 12 months upon arrival in the recipient country". However, the problems arose from misunderstanding of or failure to refer to the stated exceptions to that guideline, rather than from the text of Guideline 6 itself. In this revised edition Guideline 6 has been modified. It now allows for direct donations of drugs with a remaining shelf-life of less than one year to specific health facilities, provided assurance can be given that the drugs can be used prior to expiration.
There ar e many dif fer ent s cenar ios f or dr ug donations . They may take place in acute emergencies or as par t of development aid in non-emer gency situations. They may be cor por ate donations ( direct or through pr ivate voluntar y organizations ) , aid by gover nments , or donations aimed directly at single health facilities. And although there are legitimate dif fer ences betw een these scenarios , ther e ar e many bas ic rules f or an appropriate donation that apply to all. The G uidelines aim to des cribe this common cor e of "G ood D onation Pr actice".
This document s tar ts with a dis cuss ion on the need for guidelines , f ollow ed by a presentation of the f our cor e principles for drug donations. The guidelines f or dr ug donations are presented in Chapter I V. When neces sar y for s pecif ic situations, possible exceptions to the gener al guidelines are indicated. Chapter V gives s ome s ugges tions on other w ays that donors may help, and Chapter VI contains practical advice on how to implement a policy on drug donations.
The se G uide lin es ar e n ot i n te rn ati on al re g ul at i on s; th ey ar e i nt en ded t o ser ve as a b asis for n at ion al or i nst itut i on al gu ide line s, to be r e vi ewed, adapte d and i mp lemented by government s and or gan izati ons dealing wi th dr ug donat ion s.
II. The need for guidelines
I n the face of dis as ter and suf fering there is a natural human impulse to r each out and help those in need. Medicines ar e an es s ential element in alleviating suff ering, and inter national humanitar ian r elief ef forts can gr eatly benefit f rom donations of appropriate drugs.
U nfor tunately, there ar e als o many examples of drug donations w hich cause pr oblems ins tead of being helpful. A s izeable dis as ter does not always lead to an objective ass es s ment of emer gency medical needs bas ed on epidemiological data and pas t exper ience. Ver y of ten an emotional appeal f or mas sive medical as sistance is is s ued w ithout guidance on what are the prior ity needs. N umer ous examples of inappropriate drug donations have been r epor ted ( s ee A nnex) . The main problems can be s ummar ized as f ollow s :
• Donated dr ugs are of ten not relevant f or the emergency situation, for the diseas e patter n or for the level of car e that is available. They are often unknown to local health prof es sionals and patients , and may not comply w ith locally agr eed dr ug policies and standar d treatment guidelines; they may even be dangerous .
• M any donated dr ugs ar rive unsor ted and labelled in a language w hich is not eas ily unders tood. S ome donated drugs come under trade names w hich are not r egis ter ed for use in the recipient country, and w ithout an I nter national N onpr opr ietar y N ame ( IN N) or generic name on the label.
• The quality of the dr ugs does not always comply with standar ds in the donor countr y. F or example, donated dr ugs may have expir ed before they reach the patient, or they may be dr ugs or fr ee samples retur ned to pharmacies by patients or health profes sionals .
• The donor agency s ometimes ignores local adminis tr ative pr ocedures f or r eceiving and distributing medical s upplies . The dis tr ibution plan of the donor agencies may conflict w ith the wishes of national author ities .
• D onated dr ugs may have a high declar ed value, e.g. the mar ket value in the donor country r ather than the w or ld market pr ice. In s uch cases impor t taxes and over heads f or storage and dis tr ibution may be unnecess ar ily high, and the ( inflated) value of the donation may be deducted f r om the gover nment dr ug budget.
• D rugs may be donated in the wr ong quantities, and some s tocks may have to be des tr oyed. This is w as tef ul and cr eates pr oblems of dis posal at the r eceiving end.
There are s everal under lying r eas ons for these problems. Probably the most important f actor is the common but mis taken belief that in an acute emergency any type of drug is better than none at all. A nother important f actor is a general lack of communication between the donor and the recipient, leading to many unneces s ar y donations. This is unf ortunate because in dis as ter s ituations and w ar zones inappropr iate dr ug donations create an extra workload in sor ting, storage and distribution and can easily over stretch the capacity of precious human resources and scarce transport volume. Of ten, the total handling costs ( duties, s tor age, tr ans por t) ar e higher than the value of the drugs. S tockpiling of unused drugs can encour age pilf er ing and black mar ket s ales.
D onating r eturned dr ugs ( unused drugs retur ned to a phar macy for s af e dis pos al, or f ree s amples given to health pr of es sionals) is an example of double standards because in most countries their use would not be permitted ow ing to quality control regulations. Apar t f rom quality aspects, s uch donations also f r us tr ate management eff or ts to administer dr ug stocks in a rational w ay. Pr escriber s are conf ronted w ith many dif fer ent drugs and brands in ever-changing dosages; patients on long-ter m treatment s uf fer becaus e the s ame dr ug may not be available the next time. For these reas ons this type of donation is f or bidden in an increas ing number of countr ies and is generally dis couraged. 3 In 1994 the WH O off ice in Zagr eb iss ued s pecif ic guidelines f or humanitar ian as sistance to for mer Y ugos lavia. 4 I n view of the existence of these diff er ent dr ug donation guidelines , the need w as felt f or one compr ehens ive s et of guidelines that w ould be endorsed and used by all major inter national agencies active in emergency relief. The examples of inappropr iate donations des cr ibed her e constitute ample r eas ons to develop inter national guidelines for drug donations . I n s ummar y, guidelines are needed becaus e:
• D onor s intend w ell, but of ten do not r ealize the poss ible inconveniences and unw anted cons equences at the r eceiving end.
• D onor and r ecipient do not communicate on equal ter ms . Recipients may need s uppor t in specifying how they want to be helped.
• D rugs do not ar r ive in a vacuum. D r ug needs may vary betw een countr ies and f rom s ituation to situation. D rug donations mus t be bas ed on a s ound analys is of the needs, and their selection and distribution mus t fit w ithin existing drug policies and adminis tr ative s ystems . U nsolicited and unnecess ar y drug donations are w as tef ul and should not occur.
• The quality requirements of drugs are different from those for other donated items, such as food and clothing. Drugs can be harmful if misused; they need to be identified easily through labels and written information; they may expire; and they may have to be destroyed in a professional way.
III. Core principles
The tw elve ar ticles of the G uidelines for D rug D onations are based on f our cor e principles . The fir st and par amount principle is that a drug donation should benefit the r ecipient to the maximum extent pos s ible. This implies that all donations s hould be bas ed on an expres sed need and that unsolicited dr ug donations ar e to be discour aged. The s econd principle is that a donation should be made with full respect f or the wishes and author ity of the recipient, and be s uppor tive of existing government health policies and adminis tr ative ar rangements. The third pr inciple is that ther e should be no double s tandards in quality: if the quality of an item is unacceptable in the donor countr y, it is als o unacceptable as a donation. The four th pr inciple is that ther e s hould be eff ective communication betw een the donor and the r ecipient: donations should be bas ed on an expr es sed need and should not be s ent unannounced.
Core principles for a donation 1. Max imu m be n ef it to t h e re cip ie n t 2. Respect for wishes and authority of the recipient 3. N o dou bl e standards i n qu ali ty 4. Eff ect ive commu n icat i on b e twee n don or an d r eci pi en t
IV. Guidelines for drug donations
Selection of drugs
All drug donations should b e b ased on an expressed need and be relevan t t o the d is eas e pat tern in t h e recipien t cou nt ry. Drugs s h ou ld not b e sen t wit hout prior con sen t by th e recip ien t.

Jus tification and explanation
This provision stress es the point that it is the pr ime r es ponsibility of the r ecipients to specify their needs. I t is intended to pr event unsolicited donations, and donations w hich ar rive unannounced and unwanted. I t als o empow er s the r ecipients to r efuse unwanted gif ts .
Pos sible exceptions I n acute emer gencies the need f or pr ior consent by the r ecipient may be w aived, provided the dr ugs ar e amongst thos e f rom the WH O M odel List of Es sential D rugs 5 that are included in the U N lis t of emer gency relief items r ecommended f or us e in acute emer gencies . 2. All donated dru gs or t heir generic equivalents should be app roved f or use in the recip ien t cou nt ry an d app ear on t he national lis t of es s en tial dru gs , or, if a n at ion al list is n ot availab le, on t he WHO Mod el List of Ess ent ial D ru gs, u n less s pecif ically req uest ed ot h erwis e by th e recip ien t.
This provis ion is intended to ens ur e that drug donations comply w ith national drug policies and es s ential dr ugs pr ogrammes. I t aims at maximizing the pos itive impact of the donation, and prevents the donation of drugs which ar e unnecess ar y and/or unknow n in the r ecipient countr y. Pos sible exceptions A n exception can be made f or dr ugs needed in s udden outbreaks of uncommon or new ly emerging dis eases, since such drugs may not be approved f or use in the r ecipient countr y.
The present ation, st ren gt h and formu lation of donated d rugs s hould , as much as pos sible, be similar t o thos e of drugs com mon ly us ed in t h e recip ien t cou nt ry.
Jus tification and explanation M os t s taff working at dif f er ent health care levels in the recipient country have been trained to us e a cer tain f or mulation and dosage schedule and cannot constantly change their tr eatment pr actices . Moreover, they of ten have insuf ficient tr aining in per forming the neces s ar y dos age calculations r equir ed for s uch changes. 
Jus tification and explanation
This provis ion prevents double standar ds : drugs of unacceptable quality in the donor country s hould not be donated to other countr ies. D onated drugs should be authorized f or sale in the countr y of or igin, and manuf actur ed in accordance w ith inter national s tandar ds of G ood M anufacturing Pr actice ( GM P) .
Pos sible exceptions I n acute emer gencies the use of the WH O Cer tif ication Scheme may not be practical. However, if it is not us ed, a jus tif ication should be given by the donor. When donors provide funds to pur chase dr ugs from local producers, those which comply with national standar ds should not be excluded on the sole gr ounds that they do not meet quality s tandards of the donor country.
N o dru gs s h ou ld be d onated t hat h ave b een iss u ed t o p at ien ts an d t hen ret urned t o a p harmacy or elsewhere, or were given to h ealth prof ess ionals as free s am ples.
Jus tification and explanation
Patients r eturn unus ed dr ugs to a pharmacy to ensure their s afe dispos al; the same applies to dr ug samples that have been r eceived by health wor kers . In most countr ies it is not allow ed to is sue s uch drugs to other patients , becaus e their quality cannot be guaranteed. For this r eason r eturned dr ugs s hould not be donated either. I n addition to quality iss ues , retur ned drugs ar e ver y dif f icult to manage at the receiving end because of broken packages and the small quantities involved. 
A ft er arrival in t he recip ient coun t ry all don at ed drugs s hou
Jus tification and explanation
In many recipient countries, and especially under emergency situations, there are logistical problems. Very often the regular drug distribution system has limited possibilities for immediate distribution. Regular distribution through different storage levels (e.g. central store, provincial store, district hospital) may take six to nine months. This provision especially prevents the donation of drugs just before their expiry, as in most cases such drugs would only reach the patient after expiry. It is important that the recipient official responsible for acceptance of the donation is fully aware of the quantities of drugs being donated, as overstocking may lead to wastage. The argument that short-dated products can be donated in the case of acute emergencies, because they will be used rapidly, is incorrect. In emergency situations the systems for reception, storage and distribution of drugs are very often disrupted and overloaded, and many donated drugs tend to accumulate.
Additional exception
Besides the possible exception for direct donations mentioned above, an exception should be made for drugs with a total shelf-life of less than two years, in which case at least one-third of the shelf-life should remain.
Presentation, packing and labelling 
Justification and explanation
A ll donated drugs, including thos e under brand name, s hould be labelled als o w ith their INN or the official gener ic name. Most training programmes ar e bas ed on the use of generic names. Receiving drugs under different and often unknown brand names and without the IN N is confus ing for health workers and can even be dangerous for patients . In the cas e of injections , the r oute of adminis tration s hould be indicated.
As much as poss ible, donated dru gs should be presented in larger qu antity u nits and h osp it al packs .
Jus tification and explanation Lar ge quantity packs are cheaper, less bulky to trans port and conf or m better w ith public s ector s upply systems in mos t developing countries. This provis ion als o prevents the donation of drugs in s ample packages, which are impr actical to manage. I n precarious situations , the donations of paediatric syr ups and mixtur es may be inappr opr iate because of logistical pr oblems and their potential mis use. 
Jus tification and explanation
This provis ion is intended to f acilitate the administration, stor age and distribution of donations in emer gency situations , as the identification and management of unmar ked boxes w ith mixed dr ugs is ver y time-and labour -intens ive. This provision specif ically dis cour ages donations of small quantities of mixed dr ugs.
The maximum weight of 50 kilograms ensur es that each carton can be handled w ithout special equipment.
Information and management
Recipient s s hould be inform ed of all drug donations that are being cons idered, p repared or act u ally un der w ay.
Jus tification and explanation M any drug donations arr ive unannounced. Detailed advance inf or mation on all drug donations is es s ential to enable the r ecipient to plan f or the receipt of the donation and to coor dinate the donation w ith other sour ces of s upply. The inf or mation s hould at leas t include: the type and quantities of donated drugs including their Inter national N onpr opr ietar y N ame ( IN N) or generic name, s tr ength, dos age f or m, manuf actur er and expir y date; ref er ence to earlier corres pondence ( for example, the letter of consent by the recipient); the expected date of ar r ival and por t of entry; and the identity and contact addr es s of the donor .
In the recipient country t he declared value of a drug donation should b e based u pon t he w h oles ale p rice of it s gen eric equ ivalent in t h e recip ien t cou nt ry, or, if s uch inf orm at ion is n ot availab le, on th e w holes ale w orld-market p rice for its gen eric eq u ivalent .
Jus tification and explanation
This provis ion is needed s olely to prevent dr ug donations being valued in the r ecipient country accor ding to the r etail price of the product in the donor country. This may lead to elevated over head cos ts for impor t tax, por t clearance and handling in the recipient country. It may also res ult in a cor responding decreas e in the public s ector dr ug budget in the r ecipient countr y. Pos sible exception I n the cas e of patented dr ugs ( for w hich there is no gener ic equivalent) the w holes ale price of the nearest ther apeutic equivalent could be taken as a r ef er ence.
C ost s of in t ernat ional and local t ran sp ort , wareh ou s in g, port clearan ce an d app rop riat e s torage and h and lin g sh ould b e paid by th e d on or agen cy, u n less s pecif ically agreed oth erw is e w it h t he recipient in advance.
Jus tification and explanation
This provis ion prevents the recipient fr om being f orced to s pend eff or t and money on the clearance and transport of unannounced consignments of unw anted items , and also enables the recipient to review the lis t of donated items at an ear ly s tage.
V. Other ways donors can help
The new emergency health kit I n the acute phase of an emergency, or in the case of displacements of refugee populations w ithout any medical car e, it is better to s end a standar dized kit of dr ugs and medical s upplies that is s pecif ically des igned for this pur pos e. F or example, the new emer gency health kit, 8 which has been widely us ed since 1990 and was updated in 1998, contains dr ugs , dis pos able supplies and basic equipment needed f or gener al medical car e for a population of 10,000 f or three months . I ts contents are based on a consensus among major international aid agencies . It is per manently s tocked by s ever al major international supplier s (f or example, the Inter national D is pensary A ss ociation, Médecins S ans F rontièr es and the United Nations Children' s F und) and can be available w ithin 48 hour s. I t is es pecially r elevant in the abs ence of s pecif ic r eques ts .
Donations in cash
A fter the acute phas e of the emergency is over, a donation in cash f or local or regional purchase of essential drugs is usually much more welcome than f ur ther drug donations in kind. S uch a cas h contribution is ver y supportive to the activities of the local gover nment or coor dinating committee, it is s uppor tive to the local and r egional pharmaceutical indus try, and it may also be more cost-ef fective. In addition, prescr iber s and patients are us ually mor e f amiliar with locally pr oduced dr ugs .
Additional guidelines for drug donations as part ofdevelopment aid
When drug donations are made betw een governments as humanitar ian support in longlas ting complex emer gencies and as r egular development ( commodity) aid ther e is usually mor e time to cons ider specific demands from the recipient's side. On the other hand, ther e is als o time to link mor e res tr ictions to the donation, e.g. to pr oducts f rom manuf actur ers in the donor countr y, and to dr ugs r egistered f or us e in the r ecipient countr y. I t should be recognized that dr ugs do not arr ive in an administrative vacuum. D r ug donations s hould not cr eate an abnor mal s ituation w hich may obs tr uct or delay national capacity building in s election, pr ocurement, s tor age, dis tr ibution and r ational use of drugs. Special car e should theref ore be taken that the donated drugs r es pond to an express ed need, comply with the national dr ug policy, and ar e in accor dance w ith national tr eatment guidelines in the r ecipient countr y. A dministr atively, the dr ugs s hould be treated as if they w ere pr ocured. This means that they should be regis tered or authorized f or us e in the countr y thr ough the s ame pr ocedure that is used f or gover nment tenders . They should be enter ed into the inventor y, distributed through the exis ting dis tr ibution channels and be s ubject to the s ame quality ass ur ance procedur es . If cost-shar ing pr ocedures are oper ational in the recipient country, the donated dr ugs s hould not automatically be dis tributed f r ee of char ge.
VI. How to implement a policy on drug donations
Management of drug donations by the recipient
Define national guidelines for drug donations I t is diff icult for a r ecipient to r ef us e a donation that has alr eady arr ived. P revention is therefor e better than cur e. Recipients should indicate to their pr ospective donor s w hat kind of as s is tance they need, and how they would like to r eceive it. I f this inf or mation is provided in a pr of es s ional w ay, mos t donors will appr eciate it and w ill comply.
Theref or e, recipients s hould f irs t f or mulate their ow n national guidelines f or dr ug donations on the basis of the international guidelines. They can also be included in the national drug policy. These national guidelines should then be officially presented and explained to the donor community. O nly after they have been pr es ented and officially publis hed can they be enf orced.
D efine adm inistr ative procedur es for r eceiving drug donations
I t is not enough f or the r ecipient to adopt and publish the gener al guidelines on the s election, quality, presentation and management of dr ug donations . Adminis trative procedur es need to be developed by the r ecipient to maximize the potential benef it of drug donations. A s much as possible such arrangements s hould be linked with existing drug s upply s ys tems, but there ar e s ever al decis ions to be made w hich apply to donations only. Examples of s uch important is sues , w hich have to be addr es s ed in each countr y, ar e:
• D ecide w ho is r espons ible for def ining the needs , and w ho will pr ior itize them.
• D ecide w ho coor dinates all drug donations .
• Which documents ar e needed w hen a donation is planned; w ho s hould receive them? • Which pr ocedure is us ed w hen donations do not follow the guidelines?
• What are the cr iteria f or accepting/rejecting a donation, and w ho makes the final decis ion? • D ecide w ho coor dinates reception, s tor age and distr ibution of the donated dr ugs.
• H ow ar e donations valued and entered into the budget/expenditur e r ecor ds?
• H ow w ill inappr opr iate donations be disposed of?
Specify the needs for donated drugs
The thir d impor tant action by the recipient is to specif y the needs for donated drugs as much as pos sible. This puts the onus on the r ecipient to car ef ully pr epare requests, indicating the r equir ed quantities and pr ioritizing the items . The mor e inf or mation given, the better. I nf or mation on donations that are already in the pipeline, or anticipated, is very helpf ul to other potential donor s. F ull inf ormation f r om the side of the r ecipient is greatly appreciated by donor s and pays of f in the long r un.
Manage drugs with less than one-year expiry D rugs do not become toxic or inef fective on their date of expir y but may slowly deter ior ate depending on the pr oduct, for mulation and s tor age conditions. S ome become toxic but mos t simply lose their eff icacy. An expiry date is the date given on the individual container ( us ually on the label) of a dr ug pr oduct, up to and including w hich the product is expected to remain w ithin s pecif ications , if stor ed cor rectly. I t is es tablished for each batch by adding the shelf-life period to the date of manufacture. The r ecommendation that all dr ugs s hould have a r emaining s helf-lif e of at leas t one year upon arr ival in a recipient country is to allow for the all too f r equent in-country dis tr ibution delays. I t gives a measure of s ecurity that patients w ill r eceive drugs of good quality.
A s pecif ic exception to the one-year s helf-lif e requirement can be made f or donated drugs pr ovided that: they ar e dir ect donations to s pecif ic health facilities ; the r es ponsible professional acknowledges that (s )he is awar e they are s hor t-dated; and the quantity and the r emaining s helf-lif e allow f or proper administration, distr ibution and prescr iption pr ior to expiry. Exper ience has show n that s ome r ecipient governments have applied the G uidelines very strictly, without due consider ation of the poss ible exceptions to the gener al rule. This has r es ulted in unneces sary impounding and dis pos al of valuable donations .
Ensure rapid customs clearance of donated drugs
Rapid customs clearance is r equir ed for all donated drugs. Cus toms and health minis try of ficials managing dr ug donations cover ed by the G uidelines have the r es ponsible tas k of allow ing entr y f or us ef ul donations , w hile rejecting short-dated donations f or w hich s atis f actor y dis tr ibution pr ovisions have not been made.
M anage donated drugs carefully
The value of donated drugs can be considerable, and the gift should be tr eated w ith due expedition and car e. O n arr ival the drugs should be ins pected and their receipt confir med to the donor agency. They s hould then be s tor ed and dis tr ibuted in accor dance with normal pr inciples of good phar macy pr actice, and under the r es ponsibility of adequately tr ained prof es sionals . There must be due vigilance to ensure that donated products are not diverted for export, commercial s ale, or into illicit channels . Good donation management also includes agr eed s ys tems of accountability.
Action required from donor agencies D onor s s hould always respect the four cor e pr inciples f or dr ug donations pr esented above. Donor s s hould als o r es pect the national guidelines f or dr ug donations and r es pond to the prior ity needs indicated by the r ecipient. U nannounced donations s hould be prevented as much as poss ible.
Avoid donations of drugs with short expiry dates
The f undamental pr oblem of donated drugs with shor t expiry dates has tr oubled r ecipients for many years . On the other hand, global experiences indicate that w ellmanaged donor or ganizations and phar maceutical companies are gener ally able to avoid donating products with short expiry dates. Some large companies have product outreach programmes under which products are specifically donated from normal inventories, on the basis of an agreed-upon schedule, to meet recipients' needs.
O ne objective of the Guidelines is to reduce donations of drugs w ith s hort expir y dates thr ough better inventor y contr ol on the par t of donor companies and inter mediaries, and through better communications . Donor s and intermediar ies s hould avoid donations of dr ugs w ith s hor t expir y dates as much as poss ible.
Inform the public
The general public in the donor country is not alw ays awar e of the common pr oblems w ith drug donations. I t is therefor e impor tant that gover nments in donor countr ies make s ome eff or t to create more public awar eness on "good donor practice". The bes t moment f or this is pr obably at the time of the public appeal through the media.
Establish donor coordination
I t is recommended that within the r ecipient countr y the different donor s collabor ate in the es tablishment of a coordinating body. In emer gency situations this is ess ential. This body s hould determine the needs , pr ior ities , s torage, logistics and dis tr ibution, and act as the centr al contact point in dis cus sion with the r ecipient gover nment author ities .
The r espons ible gover nment department should s upply r elief agencies with as much inf or mation as pos sible about r eques ted and appr oved donations. Conver sely, r elief agencies s hould keep the donor coor dinating body and the r es ponsible government department fully informed of the specific identity, arrival dates, quantities, and expir y dates of donations . This will greatly assist the co-ordinating body in the recipient country to plan for the proper reception of the donations, and to identify the need for additional supplies.
Within donor countries all organizations should likewise establish a coordinating body at headquarters level, to ensure that appropriate donation policies and processes are followed.
The ar gument that pr oducts w ith short expir y dates can be donated in the case of acute emergencies , because they will be us ed r apidly, is incor rect. In emer gency situations the s ystems f or reception, stor age and distribution of drugs ar e very often disrupted and overloaded, and many donated dr ugs tend to accumulate. Armenia, 1988 A fter the ear thquake, 5,000 tons of dr ugs and medical s upplies wor th U S $ 55 million w er e s ent. This quantity far exceeded needs. I t took 50 people s ix months to gain a clear picture of the dr ugs that had been received. Eight per cent of the dr ugs had expir ed on ar rival, and 4% wer e destroyed by f rost. Of the r emaining 88% , only 30% w er e eas y to identif y and only 42% w er e r elevant f or an emer gency situation. The major ity of the dr ugs w er e only labelled with br and names. 
Annex: Examples of problems with drug donations
Eritrea, 1989
D ur ing the war f or independence, des pite caref ul w ording of appeals, many inappr opriate donations w ere r eceived. Examples w ere: s even tr uckloads of expir ed aspir in tablets that took six months to bur n; a whole container of uns olicited cardiovascular drugs with tw o months to expiry; and 30,000 half-litr e bottles of expir ed amino-acid infus ion that could not be dis posed of anywhere near a settlement becaus e of the s mell. 10 
Sudan, 1990
A lar ge consignment of dr ugs w as sent to war-devas tated souther n S udan. Each box contained a collection of small packets of dr ugs , s ome par tly used. A ll wer e labelled in Fr ench, a language not spoken in Sudan. Most dr ugs w ere inappr opriate, s ome could be dangerous. These included: contact lens s olution, appetite stimulants , mono-amine oxidas e inhibitors ( danger ous in Sudan), X-ray s olutions , dr ugs agains t hyper choles terolaemia, and expired antibiotics . O f 50 boxes , 12 contained drugs of s ome use.
11
France, 1991 P harmaciens S ans F rontières collected 4 million kilograms of unus ed dr ugs fr om 4,000 pharmacies in F rance. These w ere s orted out in 88 centres in the country. Only about 20% could be us ed for international aid progr ammes , and 80% w er e bur nt.
12
Russian Federation, 1992
Russian pharmaceutical production has fallen far below its 1990 level, and donations of drugs have been welcomed. However, initial enthusiasm soured when the nature of some donations was discovered. Examples of donations include: 189,000 bottles of dextromethorfan cough syrup; pentoxifylline and clonidine as the only antihypertensive items; triamterene and spironolactone as diuretics; pancreatic enzyme and bismuth preparations as the only gastrointestinal drugs. 13 
Guinea-Bissau, 1993
In September 1993 eight tons of donated drugs were sent; all were collected from pharmacies in quantities of between 1 and 100 tablets. The donation contained 22,123 packages of 1,714 different drugs which were very difficult to manage and greatly interfered with government efforts to rationalize drug supply and drug use. 14 
Lithuania, 1993
Eleven w omen in Lithuania temporarily los t their eyes ight af ter us ing a donated drug. The drug, clos antel, w as a veter inary anthelmintic but was mis takenly given to treat endometr itis. The dr ug had been received w ithout product inf or mation or package ins er t, and doctor s had tried to identif y the product by matching its name with those on leaflets of other pr oducts . O f all drug donations r eceived by the WH O f ield off ice in Zagreb in 1994, 15% wer e completely unus able and 30% wer e not needed. 16 By the end of 1995, 340 tons of expir ed dr ugs w ere s tor ed in M ostar . Mos t of thes e w er e donated by dif ferent Eur opean nations .
17
Rwanda, 1994
Large quantities of a sophisticated antibiotic were donated to refugee camps in Rwanda. Drugs were donated in bulk through private voluntary organizations. Refugee workers were not used to using the drug; most of it was recalled; the remainder posed disposal problems.
18,19
Bosnia and Herzegovina, 1992-1996
Between 1992 and mid-1996 an estimated 17,000 metric tons of inappropriate donations were received with an estimated disposal cost of US$34 million. 20 
Albania, 1999
A WHO audit of humanitarian drug donations received in Albania during May 1999 revealed serious quality problems. It was estimated that 50% of the drugs coming into Albania during the Kosovo refugee crisis were inappropriate or useless and would have to be destroyed. Sixty-five per cent of drugs had an inadequate expiry date (either missing or expiring less than one year from the date of donation); and 32% were identified only by brand names, which were unfamiliar to Albanian health professionals. None of the short shelf-life donations were requested, and according to aid workers they could not be distributed and used before the end of the year. 21 
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There are many types of drug donation. Some are a rapid response to an acute emergency or form a component of development aid. Others represent the philanthropic aims of large corporations. Yet others are small and targeted for use by individual health facilities. But all too often, drug donations are inappropriate and cause disposal problems for their recipients.
By describing "good donation practice", these guidelines aim to improve the quality of drug donations. As a basis for national or institutional guidelines, they can be adapted and implemented by governments and organizations dealing with this type of assistance.
First issued in 1996, the guidelines have since been revised, following an extensive review of experiences with their use. This second edition begins with a discussion of the need for guidelines and goes on to present four core principles and 12 guidelines for drug donations, covering such issues as selection of drugs, quality assurance, and presentation and packaging. Exceptions to the general guidelines are also given, to take account of specific drug donation situations. The guidelines conclude with suggestions on other ways in which donors can provide assistance, and advice on how recipients can implement a drug donations policy. This is an intergagency consensus document published by the WHO Department of Essential Drugs and Other Medicines on behalf of the organizations listed.
